SBIR/STTR Research Award
A COMPREHENSIVE DATABASE RESOURCE ON PROTEIN CATABOLISM
Award amount
$981,925Program and phase
SBIR · Phase IIAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Cognia Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): This Phase II SBIR grant will enable the
continued development of a unique and comprehensive research resource, the
Protein Catabolism Database (PCDB), which will enable scientists to build upon
a wealth of information to accelerate basic research and drug target
identification. PCDB focuses on the field of protein catabolism, aberrations of
which are implicated in cancer, neurodegeneration, inflammation, and immune
disorders. During Phase I, a sophisticated classification system of proteolysis
factors and substrates was devised, and a relational data structure created,
complete with data input and retrieval interfaces. In Phase II, PCDB will be
populated with comprehensive information on proteolysis pathways, and advanced
interfaces for data mining and visualization will be created. The ultimate goal
of PCDB is to provide academic and industrial investigators with carefully
curated, up-to-date information on proteolysis, integrated with software tools
to link specific knowledge to specific research problems. Completely unique
applications will be developed, enabling targeting of pathogenic proteins
through their proteolytic regulators, rational design of protein drugs with
consideration of their in vivo half-lives. PCDB will also be novel in its
ability to model drug effects on biological pathways, to differentiate complex
biological states, and to accept user-generated curation.
PROPOSED COMMERCIAL APPLICATION:
The Protein Catabolism Database and its integrated software suite will have commercial application in industry and academia in the genome-wide prediction of proteolysis factors and substrates, tareting of proteins through proteolytic regulators, rational design of protein drugs with targeted in vivo half-lives, in silico modeling of pathogenic and drug-induced proteolytic pathways, and analysis of protein expression data elucidating pathogenesis and toxicology.
Technology keywords
Not reported